Skip Ribbon Commands
Skip to main content


Carotid Stent System

  • Designed as a closed cell stent with the flexibility of an open cell stent1
  • Provides excellent flexibility and vessel wall apposition1
  • Conforms to tortuous anatomy1,2
  • In-vivo self-tapering to ICA-CCA* segments1

​RoadsaverTM stent has been designed to minimize the risk of peri- and early post-procedural cerebral embolization events related to the carotid artery stenting (CAS), the main CAS limitation with conventional platforms that warrant further attention in both symptomatic and asymptomatic patients​
Roadsaver is a braided nitinol carotid stent that incorporates: ​
  • Inner layer​
    • With one of the smallest pore sizes (375-700 μm) providing good plaque coverage and sustained embolic protection​
  • Outer layer ​
    • With excellent flexibility and conformability in tortuous anatomies ​
  • Low profile 5F and flexible rapid exchange delivery system for all stent sizes ​
    • Facilitating the stent delivery

​Safety and effectiveness of CAS with RoadsaverTM is supported by a large body of clinical evidence (short-/long term outcomes) in both, asymptomatic and symptomatic patients. ​

  • Low 30-day Major Adverse Event rate (i.e. death & stoke)3 ​
  • Mesh-covered stents may minimize plaque protrusion compared to conventional stents4
  • Roadsaver (micromesh) limits subclinical events during CAS procedure relative to single-layer stent5​
  • Good long-term performance of the RoadsaverTM stent up to 4 years6
  • Trans-radial approach is feasible with RoadsaverTM stent7 and may avoid cervical surgical cut-downs, reduce arch manipulation and shorten procedural time8

  1. Hopf-Jensen, S. et al.. Initial clinical experience with the micromesh Roadsaver carotid artery stent for the treatment of patients with symptomatic carotid artery disease. J Endovasc Ther 22, 220–5 (2015). 
  2. Nerla, R. et al. Carotid artery stenting with a new-generation double-mesh stent in three high-volume Italian centres: clinical results of a multidisciplinary approach. EuroIntervention 12, e677-83 (2016).
  3. Sannino et al. Catheter Cardiovasc Interv. 2018 Mar 1;91(4):751-757.doi: 10.1002/ccd.27421. Epub 2017 Dec 14.​
  4. Umemoto T, et al. EuroIntervention. 2017 Dec 20;13(11):1347-1354.​
  5. Montorsi et al. J Am Coll Cardiol Intv. 2020 Feb, 13 (4) 403–414​.
  6. Machnik et al. Postepy Kardiol Interwencyjnej. 2017;13(2):130-134. doi: 10.5114/pwki.2017.68139. Epub 2017 May 30.​
  7. Kedev S, et al.  Safety of Slender 5Fr Am J Cardiol. 2015;116(6):977-81.​
  8. Kahlberg et al. J Endovasc Ther 2021 Oct;28(5):726-736. doi: 10.1177/15266028211025046. Epub 2021 Jun 17.​

What the evidence says

Discover our clinical evidence and case studies concerning this topic.

Do you need more info about this product?

Our sales representatives are here for you.

Contact us
Send us a message
I have read and accept Terumo Privacy And Cookies Policy and the Terms Of Use*
I wish to receive information and marketing updates from Terumo.
* mandatory fields

Thank you for contacting us!

We typically respond within 2 business days and will come back to you as soon as possible.

Are you a healthcare professional?

This webpage can include promotional content regarding one or several products of Terumo Europe, or some procedures concerning the use or implantation of such products. This webpage is exclusively intended for healthcare professionals and is in no event directed to the general public

For Pharmaceutical Professionals interested in our B2B products portfolio, please visit Terumo Pharmaceutical Solutions.